Abstract

An international consensus on photodynamic therapy (PDT) for skin cancer was published in 2007 and described aminolevulinic acid (ALA)-based regimens only, as these are now relatively widely approved for skin cancer applications. Including the very first clinical report on PDT for skin cancer from over 100 years ago by von Tappeiner, photosensitizers (PSs) other than ALA-induced protoporphyrin IX have been used for cutaneous malignancies for many decades. This chapter aims to provide an assessment of the current state of these exogenous PSs in the management of skin cancers.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call